-
Business
-
Policy & Business
-
-
Federal IT
-
Information Technology
-
-
State & Local
-
State & Local Government
-
-
Defense
-
Defense & Intelligence
-
-
Healthcare
-
Healthcare Policy & IT
-
-
Energy
-
Energy Policy & Technology
-
-
Education
-
Education Policy & Technology
-
FDA Grants Expanded Use of Pfizer Cancer Drug Xalkori
The Wall Street Journal (online registration required): The U.S. Food and Drug Administration on Friday approved Pfizer Inc.’s Xalkori for treatment of a rare form of advanced non-small-cell lung cancer, making it the first therapy for the condition.
The drug’s use has been expanded to treat the roughly 1% of patients with advanced, or metastatic, non-small cell lung cancer whose tumors have an ROS-1 gene alteration, thought to lead to abnormal cells. Xalkori, or crizotinib, is the first..
Tags
Share
Top Stories
- The ‘Gateway Drug to Corruption and Overspending’ Is Returning to Congress – but Are Earmarks Really that Bad?
- Trump asked Georgia secretary of state to 'find' 11.7k ballots, recalculate election result
- Pelosi Is Narrowly Reelected Speaker
- U.S. appeals court rejects lawmaker's bid to have Pence overturn Biden's win
- Biden Team Says It's Facing 'Pockets of Resistance' in Transition
- Supreme Court Punts Census Case, Giving Trump An Iffy Chance To Alter Numbers
- Watchdog Finds Education Department’s Return to Office Plan is Generally Good
- Pete Buttigieg Could Become the First Senate-Approved out LGBTQ + Cabinet Secretary
- GovExec Daily: What Federal Execs Can Expect During the Transition
- Biden's Victory Cemented As States Reach Key Electoral College Deadline
- Trump's Legal Losses Come Fast And Furious
- Senators Raise Concerns Over Burrowing In, Other 'Midnight' Activities at VA
- How Dozens of Trump’s Political Appointees Will Stay in Government After Biden Takes Over
- Biden officially announces ex-Obama official Brian Deese as top economic adviser
- US lawmakers unveil anti-slavery constitutional amendment
- U.S. Senate panel votes to approve Trump FCC nominee
Whitepapers & Special Reports
i360Gov Newsletters
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe NowAlso in Policy & Business
About
i360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Contact Us
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
Newsletters
Copyright © 2009-2025 i360Communications, LLC.